Janssen Vaccines & Prevention B.v.

Zhaoqing Ding

Katarina Radosevic

Jan Willem Meijberg

Antonietta Impagliazzo

Michelle Wagner

Jehangir Wadia

Robert Anthony Williamson

Jan Wilem Meijberg

Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA.

Influenza virus vaccines and uses thereof

Provided herein are influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Provided herein are multimeric influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Growing community of inventors

San Diego, CA, United States of America

Zhaoqing Ding